Michael Vincent Meluzio, the Vice President and Principal Accounting Officer at Cue Biopharma, Inc., recently sold 1,144 shares of the company's common stock. This transaction was made to satisfy mandatory tax withholding obligations.
The sale took place on October 12, 2026, and was reported in a filing made on October 14, 2026. Meluzio now holds a total of 47,817 shares following this transaction.
Background
Cue Biopharma, Inc. operates in the pharmaceutical preparations sector, focusing on innovative therapies. The company is listed under the Central Index Key 0001645460 and has its headquarters in Somerville, Massachusetts. Cue Biopharma has been active in filing reports with the SEC, with its recent filings including the Form 4 submitted on October 14, 2026, and previous filings on August 17, 2026, and July 10, 2026.
What the Filing Says
The SEC filing indicates that Meluzio's sale of shares was executed automatically as part of the company's policy. According to the filing, "These sales were made automatically to satisfy mandatory tax withholding obligations through a 'sell-to-cover' transaction in connection with the vesting and settlement of restricted stock units." This means that Meluzio did not have control over the timing or price of the shares sold.
Impact
This transaction may affect Cue Biopharma's shareholder perception, as it highlights the company's adherence to its policies regarding stock sales and tax obligations. The pharmaceutical industry is closely monitored for compliance with regulations, and such transactions can influence investor confidence.
What's Next
The filing does not say what happens next.